FMP

FMP

Enter

AGTC - Applied Genetic...

photo-url-https://images.financialmodelingprep.com/symbol/AGTC.png

Applied Genetic Technologies Corporation

AGTC

NASDAQ

Inactive Equity

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

0.394 USD

0 (0%)

Historical Prices

From:

To:

page loading card

About

ceo

Ms. Susan Washer

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting centr...

CIK

0001273636

ISIN

US03820J1007

CUSIP

03820J100

Address

14193 Nw 119Th Terrace, Suite ...

Phone

13864622204

Country

US

Employee

102

IPO Date

Mar 27, 2014

Financial Statement

-20M-10M010M20M2022 Q12022 Q22022 Q32022 Q42023 Q1RevenueNet Income

Earnings

-0.6-0.5-0.4-0.3-0.2-0.102020 Q42021 Q12021 Q22021 Q32021 Q42022 Q12022 Q22022 Q3EPS Consensus

AGTC Financial Summary

CIK

0001273636

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

03820J100

ISIN

US03820J1007

Country

US

Price

0.39

Beta

1.58

Volume Avg.

1.32M

Market Cap

0

Shares

-

52-Week

0.2303-2.825

DCF

4.23

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.27

P/B

-

Website

https://agtc.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest AGTC News

PennyStocks

Oct 25, 2022

Make Money With Penny Stocks in November? 3 Methods to Use

Use these tips for profiting with penny stocks The post Make Money With Penny Stocks in November? 3 Methods to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

GlobeNewsWire

Sep 1, 2022

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor confe...

GlobeNewsWire

Aug 1, 2022

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor confere...

GlobeNewsWire

Jul 7, 2022

AGTC to Present at Upcoming American Society of Retina Speci...

July 7, 2022 at 8:00 AM EDT July 7, 2022 at 8:00 AM EDT

GlobeNewsWire

Mar 8, 2022

AGTC to Participate in Upcoming Investor Conferences

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that management will be participating in the following virtual investor conferences:

Seeking Alpha

Feb 14, 2022

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 20...

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

GlobeNewsWire

Feb 7, 2022

AGTC to Host Second Quarter Financial Results Conference Cal...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market open...

Zacks Investment Research

Nov 9, 2021

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Re...

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep